ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 1190 • ACR Convergence 2025

    IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort

    Xinli Yang1, Wen Zhang2, Jiaxin zhou3 and Yuxue Nie4, 1Peking Union Medical College, Dong Cheng Qu, China (People's Republic), 2Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), 3Peking Union Medical College Hospital, Beijing, China (People's Republic), 4Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic)

    Background/Purpose: This study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).Methods: A total of…
  • Abstract Number: 1092 • ACR Convergence 2025

    Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

    Binod Kc1, Aakritee Sharma Subedi1, Salome Walsh1, Areeba Memon1 and Andras Perl2, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY, Syracuse, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system's ability to fight cancer. However, their use is associated with immune-related…
  • Abstract Number: 0976 • ACR Convergence 2025

    LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation

    Yuan Zhan1, Colton Sanders2, Michael Diaz2, Jinmin Miao3, Arminja Kettenbach4, Zhong-Yin Zhang5, Paul Wolters6, Francesco Boin7, Stephanie Stanford2 and Nunzio Bottini8, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of California San Diego, San Diego, CA, 3Purdue University, West Lafayette, IN, 4Geisel School of Medicine at Dartmouth, Lebanon, NH, 5Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, West Lafayette, IN, 6University of California San Francisco, San Francisco, CA, 7Cedars-Sinai Medical Center, Beverly Hills, CA, 8Cedars Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: The identification of effective and safe anti-fibrotic agents is a critical unmet need in systemic sclerosis (SSc). Although fibrosis in SSc is driven by…
  • Abstract Number: 0915 • ACR Convergence 2025

    A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models

    Yuhao Qin1, Huan Wang1, Han Gao1, Chongqi Zhang1, Chengpan Wang1, yanru fan1, wei ye1, yuan lin1, Lu Su2, Wenming Ren1 and cheng liao1, 1Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China (People's Republic), 2Jiangsu Hengrui Pharmaceuticals, Shanghai, Shanghai, China

    Background/Purpose: Pathological elevation of type I interferon (IFN-I) , B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) has been robustly documented across multiple autoimmune…
  • Abstract Number: 0678 • ACR Convergence 2025

    Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients

    Andrea-Hermina Györfi1, Ayla Nadja Stuetz2, Christina Duesing3, Laura-Marie Lahu4, Franca Sophie Deicher5, Yi-Nan Li6, Celine van Saan5, Alexandru-Emil Matei7, Alexander Hoelscher5, Peter-Martin Bruch8, Sarah Koziel8, Manuel Roehrich9, Mareike Cramer10, Bernhard Homey5, Bjoern Buehring11, Alexander Kreuter12, Aleksandar Radujkovic5, Claus Peter Heußel13, Hanns-Martin Lorenz14, Ricardo Grieshaber-Bouyer15, Georg Schett16, Jörg Distler17 and Wolfgang Merkt18, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, 2Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 3Klinik für Rheumatologie, Düsseldorf, Germany, 4Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 5Uniklinik Düsseldorf, Düsseldorf, Germany, 6University Hospital of Düsseldorf, Düsseldorf, Germany, 7Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 8University Hospital Düsseldorf, Dusseldorf, Germany, 9Universitätsmedizin Mainz, Mainz, 10University Hospital Düsseldorf, Düsseldorf, Germany, 11Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, 12HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, 13Thoraxklinik, University of Heidelberg, Heidelberg, 14Universitétsklinikum Heidelberg, Heidelberg, Germany, 15University Hospital Erlangen, Erlangen, Germany, 16Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, 17University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 18University Hospital Düsseldorf, Düsseldorf, Germany

    Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
  • Abstract Number: 0858 • ACR Convergence 2025

    IgA Anti-β2GPI Antibodies Drive Proatherogenic Myeloid Activation and Vascular Dysfunction in APS

    Kavya Sugur1, Chao Liu2, Emily Chong3, Srilakshmi Yalavarthi4, Katarina Kmetova5, Wenying Liang6, Emily Becker6, Gavin Poppei6, Cyrus Sarosh7, NaveenKumar Somanathapura3, Ajay Tambralli3, Jason S. Knight3 and Yu (Ray) Zuo3, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, 2University of Michigan, Superior Charter Twp, MI, 3University of Michigan, Ann arbor, MI, 4Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, 5Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 6University of Michigan, Ann arbor, 7University of Michigan, Temperance, MI

    Background/Purpose: Cardiovascular disease is a major cause of morbidity and mortality in antiphospholipid syndrome (APS), with rates of accelerated atherosclerosis comparable to those seen in…
  • Abstract Number: 0375 • ACR Convergence 2025

    Association of Glucocorticoid Toxicity Index Scores with Quality-of-Life and Healthcare Resource Utilization at 6 Months in a Real-World Cohort of Individuals Receiving Glucocorticoids

    Naomi Patel1, Jiaqi Wang1, Isha Jha2, Grace McMahon1, Tania Chiha3, Hyon K. Choi4 and John Stone5, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, 3Mount Auburn Hospital, Boston, 4MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, 5Massachusetts General Hospital , Harvard Medical School, Concord, MA

    Background/Purpose: Glucocorticoids (GCs) are used long-term by approximately 1% of the adult population and contribute to excess morbidity and mortality. We prospectively assessed Glucocorticoid Toxicity…
  • Abstract Number: 0272 • ACR Convergence 2025

    Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice

    Rafael Gálvez Sánchez1, José Luis Martín-Varillas2, Lara Sánchez Bilbao3, Ivan Ferraz Amaro4, Elena Aurrecoechea5 and Ricardo Blanco3, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 2Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 3Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Hospital Sierrallana, CANTABRIA, Spain

    Background/Purpose: Ocular involvement is a potential severe complication of Behçet’s Disease (BD). The traditional classification, by the International Study Group (ISG, 1990) requires the mandatory…
  • Abstract Number: 0213 • ACR Convergence 2025

    Development of a Predictive Tool for Obstetric Risk Stratification in Autoimmune Rheumatic Diseases: A Meta-Analysis-Based Model

    Noe Macias-Segura1, Rodolfo Martinez-Canales1, Braulio R. Avalos-Garcia2, Andres M. Ortiz-Rios2, Eva Abigaid Galindo-Calvillo2, Mario Cesar Salinas-Carmona1, Lorena Perez-Barbosa2, Dionicio A. Galarza-Delgado3 and Cassandra Michele Skinner-Taylor2, 1Immunology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 2Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Nuevo Leon, Mexico, 3Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Autoimmune rheumatic diseases (ARDs) such as systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), and Sjögren's syndrome significantly increase the risk of…
  • Abstract Number: 0109 • ACR Convergence 2025

    Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation

    Juan Liang1 and Yinlian Zhang2, 1Gempharmatech, Nanjing, Jiangsu, China, 2GemPharmatech, Nanjing, China (People's Republic)

    Background/Purpose: Psoriatic arthritis (PsA), a complex inflammatory disorder that affects up to 30% of psoriasis patients. It is marked by clinical heterogeneity and a lack…
  • Abstract Number: 0013 • ACR Convergence 2025

    Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases

    Xiaofeng Zhao1, Xiaoqing Liu1, Yuxi Yan2, Tiezheng Liu3, Yong Fu3, Yulan Hu2, Kangmin Zhou2, Minyun Zhou4, Yingying Hu2 and Shunwei Zhu2, 1State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 2State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), 3State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), 4State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing

    Background/Purpose: B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that contributes to the regulation of T cell, B cell and dendritic cell…
  • Abstract Number: PP05 • ACR Convergence 2025

    Mastering a Rare, Autoimmune Disease: My Journey Regaining Agency Through Education, Collaboration, and Community

    Mustafa Shameem

    Background/Purpose: After a complex diagnostic journey, my PCP working on a rheumatological theory ordered a myositis-specific autoantibody (MSA) panel. It revealed the presence of an…
  • Abstract Number: 2600 • ACR Convergence 2025

    Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution

    Nicholas Sugiarto1, Michelle Curtis2, Siddarth Gurajala2, Thomas Eisenhaure3, Qian Xiao4, Joseph Mears5, Arnon Arazi6, Paul Hoover7, Celine Berthier8, Saori Sakaue9, Andrea Fava10, David Hildeman11, E. Steve Woodle12, Brad Rovin13, Jennifer Barnas14, Maria Dall'Era15, Chaim Putterman16, Diane Kamen17, Maureen McMahon18, Jennifer Grossman19, Kenneth Kalunian20, Jeffrey Hodgin21, Fernanda Payan Schober22, Mariko Ishimori23, Michael Weisman23, William Apruzzese24, Joel Guthridge25, Michael Brenner26, Jennifer Anolik27, David Wofsy28, Judith James25, Deepak Rao7, Anne Davidson29, Michelle Petri30, Jill Buyon31, Nir Hacohen32, Betty Diamond33 and Soumya Raychaudhuri7, 1Harvard Medical School, Brookline, MA, 2Harvard Medical School, Boston, 3Broad Institute, Cambridge, MA, 4Harvard Medical School, Boston, MA, 5Michigan University, Ann Arbor, MI, 6Feinstein Institutes for Medical Research, Acton, MA, 7Brigham and Women's Hospital, Boston, MA, 8University of Michigan, Ann Arbor, MI, 9University of Washington, Yokohama, Japan, 10Johns Hopkins University, Baltimore, MD, 11Cincinnati Children's Hospital, Cincinnati, OH, 12UC Health, Cincinnati, 13The Ohio State University, Columbus, OH, 14University of Rochester, Rochester, NY, 15Division of Rheumatology, University of California, San Francisco, CA, 16Albert Einstein College of Medicine, Safed, Israel, 17Medical University of South Carolina, Johns Island, SC, 18UCLA David Geffen School of Medicine, Los Angeles, CA, 19UCLA, Sherman Oaks, CA, 20UC San Diego, La Jolla, CA, 21University of Michigan, Ann Arbor, 22TTUHSC, El Paso, TX, 23Cedars-Sinai Medical Center, Los Angeles, CA, 24Pfizer, Boston, 25Oklahoma Medical Research Foundation, Oklahoma City, OK, 26Brigham and Women's Hospital, Harvard Medical School, Newton, MA, 27University of Rochester Medical Center, Rochester, NY, 28University of California San Francisco, SF, CA, 29Feinstein Institutes for Medical Research, Manhasset, NY, 30Johns Hopkins University School of Medicine, Timonium, MD, 31NYU Grossman School of Medicine, New York, NY, 32Broad Institute of MIT Harvard, Cambridge, MA, 33The Feinstein Institutes for Medical Research, Manhasset, NY

    Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
  • Abstract Number: 2491 • ACR Convergence 2025

    High Prevalence of Autoimmunity and Cancer in Anti-NOR90-positive Patients: A Multicenter Observational Study

    Marina Dueñas-Ochoa1, Cristina Valero2, Francisco Morandeira3, Juan Carlos Sáez1, Maryia Nikitsina4, Montserrat Roig Kim5, Laia De Daniel Bisbe5, Esther Vicente-Rabaneda6, Arantza Alfranca1, Miguel A. González-Gay7, Martí Aguilar Coll8, Rosario Garcia Vicuña6, Javier Narváez9 and Santos Castañeda10, 1Hospital La Princesa, Madrid, Spain, 2Hospital de la Princesa, Madrid, Spain, 3Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, 4University Hospital La Princesa, Madrid, Madrid, Madrid, Spain, 5Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, 6Hospital Universitario de La Princesa, Madrid, Spain, 7Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, 8Hospital Bellvitge, Barcelona, Spain, 9Hospital Universitario de Bellvitge, Barcelona, Spain, 10Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain

    Background/Purpose: Anti-Nucleolar Organizer Region 90 (anti-NOR90) antibodies target nucleolar proteins involved in ribosomal RNA transcription and processing, key steps in protein synthesis. These antibodies have…
  • Abstract Number: 2396 • ACR Convergence 2025

    A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases

    Gerber Gomez1, Yipeng Cheng2, Kristiana Nita2, Michael Hausmann3, Christian Fischer1 and Yasemin Ataman-Önal3, 1Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland, 2AliveDx, Edinburgh, United Kingdom, 3AliveDx Suisse SA, Eysins, Switzerland

    Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology